RV Systolic Remodeling in PAH
Building on the previous studies of Fine et al 7 and Ryo et al, 8 we hypothesized that a simple index that would incorporate both the longitudinal component of RV adaptation and end-systolic dimension would carry strong prognostic information in PAH. In this study, we propose a novel and simple RV end-systolic remodeling index (RVESRI) defined as the ratio of end-systolic RV free wall longitudinal length:septal height (RVESRI=end-systolic lateral free wall length/septal height). Internal scaling free wall length to septal length rather than body surface area may have the advantage of scaling using the same dimension (dimensional consistency) and being less influenced by edematous state or obesity. Moreover, we hypothesized that internal scaling to septal height may partially correct for apical foreshortening.
This prospective registry study had 4 main objectives. Our first objective was to assess the connectivity between different right heart parameters and to determine whether RVESRI is centrally connected to other right heart parameters. Our second objective was to determine whether RVESRI would be complementary to well-validated prognostic scores in PAH, 3, 5, [9] [10] [11] including the Registry to Evaluate Early and LongTerm PAH Disease Management (REVEAL) score and the Pulmonary Hypertension Connection equation. Our third objective was to determine the factors influencing changes in RVESRI at 1 year and relationship with outcome. Finally, our last objective was to compare in a new series the test-retest characteristics of RVESRI and RVLS.
Methods
Between August 2005 and May 2014, 245 patients with PAH were included in the prospective Vera Moulton Wall Center Pulmonary Hypertension Registry at Stanford. Inclusion criteria were diagnosis of PAH according to the guidelines (mean pulmonary arterial pressure ≥25 mm Hg and pulmonary arterial wedge pressure ≤15 mm Hg 2 and NT-proBNP levels available within 2 weeks of echocardiography in stable condition. Exclusion criteria were the following: congenital systemic-to-pulmonary shunts (n=10); complete echocardiographic study not available for review (n=6); or advanced cancer at baseline (n=1). One-year follow-up echocardiograms were available in 203 patients. By design, patients with pulmonary hypertension WHO classes other than group 1 pulmonary hypertension (PH) were not included in this study. 2 Stanford University Institutional Review Board approved the study, which was conducted in agreement with the Helsinki-II declaration. All patients gave written informed consent.
Hemodynamic Assessment
Right heart catheterization within 3 months of inclusion (available within a week for 77% of patients) was performed through the internal jugular or right femoral vein. RAP, systolic pulmonary arterial pressure, mean pulmonary arterial pressure and diastolic pulmonary arterial pressures, pulmonary arterial wedge pressure, pulmonary vascular resistance and pulmonary vascular resistance index (measured as transpulmonary gradient divided by cardiac index), and cardiac index (using the thermodilution method) were measured.
Echocardiographic Assessment
Digitized studies were acquired using Hewlett Packard Sonos 5500 or Philips IE 33 ultrasound systems (Philips, Amsterdam, The Netherlands). All measures were averaged over 3 cycles and analyzed according to the latest guidelines by 2 blinded certified readers (M.A. and F.H.). 12, 13 Indices of right heart remodeling and function were measured on the focused RV apical 4-chamber view; measures included end-diastolic and end-systolic areas both indexed to body surface area, maximal right atrial area index, RV fractional area change, tricuspid annular plane systolic excursion, and end-systolic left ventricular eccentricity indices.
14 RV free wall Lagrangian longitudinal strain (RVLS) was measured from midendocardial end-diastolic and end-systolic manually traced lengths and calculated as (end-systolic length−end-diastolic length)/end-diastolic length; values for RVLS Figure 1 . Illustration of measurements of selected right heart metrics in end diastole (left) and end systole (right). Right ventricular endsystolic remodeling index (RVESRI) represents a simple ratio of end-systolic lateral length:septal height (representing RV longitudinal length measured straight from the septal tricuspid annulus point to the RV insertion on the interventricular septum). *Note the exclusion of the right atrial appendage. RA indicates right atrium; RVEDA, RV end-diastolic area; RVESA, RV end-systolic area; and TAPSE, tricuspid annular plane systolic excursion. RV Systolic Remodeling in PAH are presented in absolute values in the text for consistency with other right heart metrics. 12 As presented in the introduction, RVESRI was defined as the lateral wall:septal wall height ratio (Figure 1 ). The lateral wall length was measured from the lateral tricuspid annulus to the insertion point of the RV on the interventricular septum. The septal height (representing the RV length at the level of the septum) was measured as a straight line from the septal tricuspid annulus to the RV insertion on the interventricular septum. Other measured of endsystolic dimensions consisted of end-systolic area indexed to either body surface area or height 1.7 , RV free wall length indexed to height or diastolic septal height, minor RV dimension, and minor (ie, lateral to septal) axis:long axis ratio. 12 RAP was estimated from the inferior vena cava size and collapse according to recent guidelines and RV systolic pressure from the tricuspid regurgitation maximal velocity and estimated RAP. 15 Pericardial effusion was considered significant if >5 mm in diastole.
Clinical and Laboratory Data
NYHA functional class, six-minute walking distance (m), diffusing capacity of the lung for carbon monoxide, serum creatinine, total bilirubin, and serum NT-proBNP (Roche Diagnostics, Mannheim, Germany) were also available within a month of echocardiography.
Follow-Up and End Points
Patients were prospectively followed after enrollment in the registry. Follow-up was concluded on April 2016. The primary combined end point was death, lung transplantation, or hospitalization for acute right heart failure. Death was verified by through the National Social Security Death Index, whereas lung transplantation and hospitalization for heart failure (defined by >24 hours of hospitalization) was verified through chart review and follow-up. The secondary end point consisted of death or lung transplant.
Risk Scores in PAH
The following scores were calculated for each patient (Table I in 5 Scottish composite score, 10 Right Heart score, 11 and the Mayo Clinic risk model. 7 There was 22% overlap between the cohorts evaluated to derive the Right Heart score derived from Stanford cohort and the present cohort.
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Healthy Controls
Eighty healthy controls were selected from the Stanford Healthy Aging research database, with a similar age range and sex ratio as patients with PAH. PH or heart failure was ruled out by a 60-point health questionnaire, physical examination, and echocardiography.
Reproducibility
Intra-and interobserver reproducibility was prospectively assessed in 14 consecutive patients with PAH assessed at Stanford Echocardiography laboratory in the month of November and December 2016. Test-retest was performed using 2 consecutive acquisitions acquired by 2 different sonographers. Using 3D echocardiography and QLab software analysis, we derived an optimally focused RV apical 4-chamber view (angle 1) and suboptimally focused RV view (angle 2). The suboptimally focused RV plane passed through the smallest transverse RV diameter while still visualizing tricuspid valve opening (angle varied between 15° and 40°).
Statistical Analysis
Data are summarized as mean±SD for continuous variables if following a normal distribution or median and interquartile range otherwise, and number of subjects (%) for categorical variables. Comparisons between groups were performed using 2-sided Student t-tests, MannWhitney test, or χ 2 test. On the basis of Ryo et al 8 previous study, we explored the relationship between RV systolic pressure and RVESRI or RVESAI to determine 3 zones of adaptation (ie, adapted, adversely remodeled, and severely adversely remodeled) using polynomial function. Partial correlation analysis was used to determine independent correlations between right heart metrics and their connectivity. 16 Cox proportional hazards regression models were used to define association CI indicates confidence interval; CTD, connective tissue disease; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; MDRD, Modification of Diet in Renal Disease; NT-proBNP, N-Terminal Pro-B-Type Natriuretic Peptide; NYHA, New York Heart Association; RAP, right atrial pressure; RVEDAI, right ventricular end-diastolic area indexed on body surface area; RVESAI, right ventricular end-systolic area indexed on body surface area; RVESRI, right ventricular end-systolic remodeling index; RVFAC, right ventricular fractional area change; RVLS, right ventricular free wall longitudinal strain; RVSP, right ventricular systolic pressure; and TAPSE, tricuspid annular plane systolic excursion.
*Hazard ratio is adjusted by the SD of the variable considered. RV Systolic Remodeling in PAH or admission at 3 years was performed using C statistic calculated for a binary outcome. Patients included in 2014 with <3 years follow-up (n=14) were right censored; the outcome at the end of follow-up was used. The incremental value of RVESRI or RVLS to risk scores was assessed by comparison of χ 2 values and C statistics. The added ability of RVESRI to predict events was also assessed using the net reclassification improvement (NRI) as described by Pencina et al. 17 To calculate the continuous NRI, the 3-year risk for the event was predicted for each subject from a Cox model with and without RVESRI and RVLS. P(up/event) was the percentage of patients with events whose predicted probability is increased by adding the echocardiographic variable to the model and P(up/nonevent) the percentage of patients without events whose predicted probability is increased. The NRI was calculated as 2*[P(up/event)−P(up/nonevent)]. Predictive scores for the primary end point were then developed from the final multivariable model and the Mayo Clinic multivariable model. Continuous variables were categorized according to clinically relevant cutoff points, RVLS thresholds from Fine et al 7 study (≥25%, [20-25[, [15-20 [, <15%) 7 and quartiles for RVESRI. Points were given according to the hazard ratio using multivariable analysis rounded to the nearest integer. Discrimination obtained with the scores was assessed using C statistic and its 95% confidence interval (CI). Change in RVESRI between baseline and 1 year was predefined as improving if >10%, worsening if <−10%, or stable otherwise. Multivariable model was used to determine associates with improvement in RVESRI. Reproducibility was expressed by intraclass correlation coefficient. Results were considered significant when 2-sided P values were <0.05. Statistical analysis was performed using SPSS statistical software (SPSS V.19, Inc, Chicago, IL).
Results
Study Population
In total, 228 patients were included in the study ( Table 1 ). The study population represents patients with PAH over a wide range of disease severity, as shown by mean pulmonary arterial pressure of 49±16 mm Hg, pulmonary vascular resistance index ranging from 3 to 54 WU m 2 , and cardiac index from 1.1 to 6.0 L min
. No patients were lost during an average follow-up of 3.9±2.4 years (median 3.7 years ranging from 40 days to 10.8 years).
Right Heart Indices and Partial Correlation Analysis
Patients presented a wide range of ventricular size and function (RVLS in absolute value from 7% to 31%, tricuspid Partial correlation analysis, which highlights the independent associations between parameters, showed that the 2 most connected metrics based on the number of direct connections were RVESRI and right atrial area index. Log NT-proBNP was connected to the network but demonstrated low connectivity, although diastolic wall stress modeling was not assessed in this study (Figure 2 ).
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Right Heart Remodeling-Pressure Relationship
The relationship between end-systolic remodeling indices (RVESRI and RVESAI) and RV systolic pressure, estimated using polynomial function, identified different zones of ventricular adaptation (Figure 3) . On the basis of the morphology of the polynomial curve, 3 zones could be described, that is, adapted (n=71 patients), adversely remodeled (n=132), and severe adversely remodeled RV (n=25). The first zone was defined by the transition between linear and curvilinear relationship (RVESRI, 1.35), which was equal to the 95th percentile of healthy controls. The second was defined by the point where progressive enlargement was associated with a decrease in RV systolic pressure (RVESRI, 1.70). Similar thresholds were found using the relationships between RVESRI and invasive measurement of pressure (mean pulmonary arterial pressure) and resistance level (pulmonary vascular resistance index), as presented in Figure I in the Data Supplement.
Clinical Outcomes
During a mean follow-up of 3.9±2.4 years, the primary end point of death, transplant, or admission was reached in 88 patients (43 died, 15 were transplanted, and 30 were admitted). Event-free survival rates for the primary end point were 90.6 (CI, 86.7%-94.5%) at 1 year, 78.0 (CI, 72.3%-83.7%) BSA indicates body surface area adjusted on the ideal body weight; CI, confidence interval; HR, hazard ratio; L1, end-systolic free wall length; RV, right ventricle; RVESA, RV end-systolic area; and RVESRI, RV end-systolic remodeling index.
*HR of the variable using univariable Cox regression analysis of correlates of the primary end point (death or lung transplant or admission for heart failure) during follow-up, adjusted by the SD of the variable considered.
†Multivariable Cox regression models (enter) for the primary end point, including the RV remodeling variable, New York Heart Association classes III/IV and log N-Terminal Pro-B-Type Natriuretic Peptide. RV Systolic Remodeling in PAH at 3 years, and 64.8 (CI, 57.5%-72.1%) at 5 years. The secondary end point of death or transplant was reached in 58 patients (43 deaths and 15 transplants). Event-free survival rates (secondary end point) were 91.0 (CI, 87.3%-94.7%) at 1 year, 80.4 (CI, 74.9%-85.9%) at 3 years, and 72.5 (CI, 65.8%-79.2%) at 5 years.
Univariable and Multivariable Analysis
The strongest univariate variables associated with the primary end point included NYHA class, RVESRI, RVLS, and log NT-proBNP (Table 3) . Whether a patient had prevalent or incident PAH was not significantly associated with outcome (P=0.24), although there was a trend for patients with incident PAH to have worse outcome. Table II in the Data Supplement compares the characteristics of patients with or without the primary end point at 3 years. When comparing the different indices of RV end-systolic size or the traverse:longitudinal ratio, RVESRI was more closely associated with outcome (Table 4) . Kaplan-Meier survival curves for the primary end point (Figure 4) show the different survival curves according to RVESRI quartiles, RVLS quartiles, thresholds of RVESRI adaptation zones, and RVLS according to previously published thresholds. 7 Similar results were found when using the secondary end point of death or lung transplant ( Figure II To minimize overfitting the multivariable model, only 7 variables were included in addition to age and sex: NYHA class, RVESRI, RVLS, log NT-proBNP, pericardial effusion, RAP, and connective tissue disease cause. The choice of variables was based on the following rationale: (1) NYHA class III or IV as previously reported, (2) RVESRI emerged as a strong novel metric, (3) RVLS was also associated to outcomes in the Mayo Clinic cohort, 7 (4) pericardial effusion, (5) log NT-proBNP emerging in many studies, including the REVEAL registry score, (6) RAP, a validated strong predictor of outcome, and (7) connective tissue disease cause as often found to be associated with poor outcome. Renal dysfunction had significant interactions with RAP and NT-proBNP (P<0.0001) and thus was not included as a covariate in the model. On multivariable analysis, NYHA class III or IV, RVESRI, and log NT-proBNP were retained in the model for the primary end point (χ 2 , 62.2; P<0.0001; Table 3 ). For the secondary end point of death or transplant, RVESRI (1.50; CI, 1.10-2.04) and log NT-proBNP (1.85; CI, 1.32-2.58) were also retained (χ 2 , 42.40; P<0.0001).
Incremental Value of RVESRI and RVLS to Risk Scores
In this cohort, validated risk scores were predictive of outcome ( Figure 5A ) with the strongest score being the REVEAL registry score (P<0.001 when compared with the P=0.06 compared with the Right Heart score). Patients were combined in 3 REVEAL groups (REVEAL 1=low, REVEAL 2-3=average/moderate high, and REVEAL 4-5=high/very high) to balance groups in terms of number of patients. The REVEAL score groups were validated in our cohort ( Figure 5B ). Adding RVESRI to validated scores, using Cox regression analysis, improved discrimination for the Pulmonary Hypertension Connection, the REVEAL, the Right Heart score, and the Scottish score ( Figure 6A ). RVLS also improved discrimination of the REVEAL score. The incremental value of RVESRI to the REVEAL score in predicting outcome was also illustrated in the Kaplan-Meier curves divided according to the different strata of risk (low score, average and moderate high score, and high and very high score; Figure 6B and 6C). The NRI (%) of the REVEAL score with RVLS was 1.05 (CI, −31.3% to 33.4%), P=0.95, the NRI of the REVEAL score with RVESRI was 45.9 (CI, 14.4%-77.4%), P<0.01, and NRI of the REVEAL score with RVLS and RVESRI was 42.6 (CI, 11.0%-74.2%), P<0.01. Scores derived from the Mayo Clinic and our derivation models were constructed (Table 5) . Five-year Kaplan-Meier survival curve of our derivation score divided into 5 groups according to the distribution of patients is presented in 
Change in RVESRI During Follow-Up
Follow-up echocardiograms were available in 203 patients (98% of 1-year survivors). The relative changes in RVESRI showed a normal distribution ( Figure 7A) . At 1 year, RVESRI was significantly associated with outcome (hazard ratio, 2.22; CI, 1.83-2.70; P<0.0001), as did the baseline values ( Figure  V in the Data Supplement). Moreover, the change in RVESRI over time was also related to outcome ( Figure 7B ). When dividing patients according to the 3 groups according to the REVEAL registry score, change in RVESRI was significantly incremental for predicting outcome in patients in the low risk or high/very high risk strata (Figure 7C and 7D) . Patients in whom prostanoids were initiated during the first year improved to a greater extent their RVESRI than the other patients, as shown in Figure 7E . On multivariable analysis, improvement in RVESRI was associated with new prostanoid therapy (odds ratio, 3.12; 95% CI, 1.08-9.02; P=0.04) and baseline RVESRI (OR, 2.65; 95% CI, 1.47-4.75; P=0.001) but not the status of incident case (P=0.08).
Variability and Reproducibility of RVESRI
Recognizing that a nonfocused RV view can influence the reliability of RV measures, we investigated in a new cohort of patients with PAH the effects of different apical angle planes. In this cohort of 14 patients, RVLS ranged from 7% to 23% and RVESRI varying from 1.2 to 1.9 and was normally distributed. Compared with RVLS and other functional and structural indices, RVESRI was less influenced by different apical 4-chamber views (angle change) and showed the best intra-and interobserver variability assessed by intraclass correlation coefficient and test-retest characteristics (Figure 8 ; Table III in the Data Supplement).
Discussion
The main finding of our study is that a simple index of RV endsystolic remodeling carries a strong prognostic value in PAH. Our findings also externally validate the prognostic value of RVLS in PAH and confirm the robustness of the REVEAL registry score. Finally, our study is the largest to date to analyze changes in RV remodeling over time and to explore its association with response to therapy.
Our study highlights the importance of RV adaptation in PAH. Research in PAH has often been focused on identifying an adapted and maladapted right heart phenotype. 19 Identifying phenotypes of RV adaptation can, however, be challenging because thresholds may be arbitrary, and rest parameters may not capture the complexity of adaptation. Acknowledging these limitations, we identified similarly to Ryo et al 8 methodology 3 zones of adaptation based on the RV end-systolic dimension to pressure relationship. The first zone is characterized by minimal RV enlargement in the presence of increasing RV pressure, whereas the third zone is characterized by a failing right heart with progressive RV enlargement and decrease in pressures, reflecting decrease Continuous variables were categorized according to clinically relevant cutoff points, RV free wall longitudinal strain thresholds from Fine et al 7 study (≥25%, [20-25[, [15-20[, <15% ) and quartiles for RV end-systolic remodeling index. Points were given according to the hazard ratio using multivariable analysis rounded to the nearest integer. In our cohort, the derivation model score ranged from 0 to 10 as follows: 35 patients with 0, 31 with 2, 44 with 44, 1 with 4, 37 with 5, 19 with 6, 7 with 7, 31 with 8, and 23 with a score of 10. NT-proBNP indicates N-Terminal Pro-B-Type Natriuretic Peptide; NYHA, New York Heart Association; and RV, right ventricular. RV Systolic Remodeling in PAH in cardiac output. This classification in 3 stages seems more appropriate than a simple separation between adapted and maladapted, although more complex analysis should also take into account the load imposed on the ventricle, diastolic characteristics, and neurohormonal and immunologic components of adaptation. [19] [20] [21] [22] Our multivariable model, as 7 proposes the combination of 3 simple parameters (ie, NYHA functional class, NT-proBNP level, and either RV end-systolic remodeling or longitudinal strain) that may help identifying the continuum of RV maladaptation profiles. Our study represents the largest validation of RVLS in an independent cohort. Although strain is a more recent concept in the field, several pioneering works have been done on end-systolic dimensions in left heart failure, including the landmark 1984 study of Carabello et al 23 placing end-systolic dimensions and stress-corrected end-systolic dimensions as the best predictors of postoperative recovery in valvular heart disease.
One important contribution of our study is the demonstration of the connection of RV end-systolic indices to right atrial dimensions and RVLS, which may contribute to their strong relationship with outcome. Although we cannot prove it in our study, one could hypothesize that a strongly connected parameter could carry more prognostic value. The index proposed in our study has the advantage of simplicity and reproducibility. In fact, RVESRI is less influenced by apical planes than other indices and has better test-retest characteristics. We have additionally demonstrated that internally scaling to septal height carries more prognostic information than scaling to height or body surface area. Compared with other remodeling indices, such as RV sphericity, RVESRI is more predictive of outcome in PAH. As RVESRI integrates ventricular enlargement, it can be questioned whether this index would be validated in other conditions, such as left heart failure, in which the range of RV dilation is lower. It is indeed unlikely to be as highly prognostic in patients with heart failure with preserved ejection fraction in whom strain has been validated as an early marker of RV dysfunction. 24 Although derived using echocardiography, RVESRI could be applied in PAH using cardiac magnetic resonance imaging 4-chamber plane, which is a more reproducible imaging modality. Several cardiac magnetic resonance metrics have been validated for prognosis in PAH (RV end-systolic volume, ejection fraction, and stroke volume index), and it remains to be assessed whether RVESRI may complement them. 25, 26 Practically, 1 important question that arises when considering risk models is whether it is time to move beyond prediction in PAH 27 because several models have already been published. 3, 5, 6, [9] [10] [11] The REVEAL registry score, derived from multicenter collaborations, emerged as a strong predictor of outcome in our cohort (with similar C statistics), highlighting both its robustness and the representability of our study population. 5, 28 In our opinion, the most important contribution of any novel imaging biomarker will be to simplify the number of parameters needed to build robust prediction score in PAH. Although novel imaging parameters like ours may improve already existing scores, their contribution will indeed likely be relatively moderate. Perhaps, more meaningful will be the contribution of incorporating stability over time or the response to therapy or as this can lead to reclassification of risk, as suggested by our findings. More studies will be needed to confirm and explore the incremental value of dynamic changes in RV end-systolic remodeling, for example, to stratify randomization of clinical trials. Our results suggest that patient with low REVEAL score but high RV end-systolic index may need closer monitoring of their evolution, and they may benefit from more intensive therapy or combined therapies.
Study Limitations
The first limitation comes from the single-center study design. However, it was primarily intended as a validation of previous studies and a comparison between end-systolic indices and longitudinal strain. Moreover, the population is a representative of major contemporary large cohort (such as the REVEAL registry). The second limitation could emerge from the mixed cohort, including both incident and prevalent cases. However, we found no significant interaction of this status with the results, although there was a trend for worse outcome in incident cases. Third, connective tissue disease cause did not emerge as an independent predictor of outcome in our cohort, contrary to the REVEAL registry. The small number of patients and the exclusion of patients with interstitial lung disease may have precluded our study to capture this risk; some of the risk may have already been accounted by other indices, such as NT-proBNP. Fourth, we assessed the incremental value of change in RVESRI at 1 year using the baseline REVEAL score and not at 1 year because catheterization was not systematically repeated at 1 year (reflecting the majority of clinical practice). Fifth, the score derived from our multivariable analysis is a simple proof-of-concept score that did not underwent calibration and used a simple ponderation, derived from the hazard ratios. Finally, the manual determination of Lagrangian strain may be questioned. In our laboratory, we have found this to be more reproducible because we use careful landmarks and we have previously shown the excellent reliability of manual derived strain values in the left heart. 29, 30 The validation of the normative values of RV strain in our healthy cohort and the validation of the thresholds described by Fine et al 7 both support the validity of our method. 12 In conclusion, this study highlights the importance of RV end-systolic remodeling for risk stratification in patients with PAH. More studies will be needed to confirm the incremental value of dynamic changes in RV end-systolic remodeling on the REVEAL score, especially in the intermediate-risk groups and as markers of response to therapy.
